Clinical use of CRISPR-Cas proteins for genome engineering is constrained by their large size, limiting in vivo delivery. To address this, we engineered an ultracompact and versatile platform from a minimally active, 400-amino acid Cas12f protein from Blautia lenta. A multi-stage strategy of structure-guided protein mu...
Dongkyeong Kim, Chia-Wei Huang, Richard Pan et al.· Molecular Therapy: Nucleic A...· 0 citations
Inclisiran may represent another milestone in the treatment of dyslipidemia, and the associated mechanism of action, pharmacology, clinical trial data, efficacy, safety, use in special populations, and adverse effects are comprehensively discussed.
Xue-Bing Wu, Jing Zhang· Reviews in cardiovascular me...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.